Glenmark Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Glenmark Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹259 of operating cash. Higher than 92% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹259Over the last 3 years, every ₹100 of reported profit came with ₹259 of operating cash.
Higher than 92% of Healthcare companies in India.
Self-Funding Ratio
0.8×Over the last 3 years its own operating cash paid for 78% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 72% of Healthcare companies in India.
Cash Locked Ratio
₹26For every ₹100 of sales, ₹26 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹32 tied up three years earlier.
More money tied up than 55% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹20Sales grew 46% in 3 years; of every extra ₹100 of sales, ₹20 became extra profit.
Higher than 60% of Healthcare companies in India.
Asset Productivity Ratio
+46% / +3%In 3 years sales changed by +46% while total assets changed by +3%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+1%Cash, after subtracting all debt, equals 1% of its market value (net cash).
Higher than 64% of Healthcare companies in India.
Tangible Assets Ratio
87%Of every ₹100 the company owns, ₹87 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 75% of Healthcare companies in India.
Tangible Net Worth Ratio
76%Of every ₹100 of net worth, ₹76 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 76% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Glenmark Pharmaceuticals Limited owes ₹0.47 for every ₹1 it owns. Net profit rose 30% in the year to Mar 2026, and grew 66% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
34.5Investors pay ₹34.5 for every ₹1 of Glenmark Pharmaceuticals Limited's yearly profit, lower than 55% of Healthcare companies in India.
P/B ratio
5.90The share price is 5.90 times Glenmark Pharmaceuticals Limited's book value per share, higher than 65% of Healthcare companies in India.
Market cap
₹62,047 CrThe total market value of all of Glenmark Pharmaceuticals Limited's shares at today's price (share price × number of shares), larger than 91% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹10,512 CrWhat Glenmark Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹372.47Net worth divided by the number of shares. The share price of ₹2,198 is 5.9 times this, which is the P/B above.
Return on equity (ROE)
17.1%Glenmark Pharmaceuticals Limited earned 17.1% on its shareholders' money over the last year, higher than 67% of Healthcare companies in India.
Owes vs Owns
0.47×Glenmark Pharmaceuticals Limited owes ₹0.47 for every ₹1 it owns (low), higher than 78% of Healthcare companies in India.
Dividend yield
0.11%Glenmark Pharmaceuticals Limited pays 0.11% of its share price as dividends a year, lower than 86% of dividend-paying Healthcare companies in India.
Revenue growth
+27%Revenue rose 27% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Profit growth
+30%Net profit rose 30% in the year to Mar 2026, and grew 66% a year on average over 3 years.
Profit margin
8.1%Glenmark Pharmaceuticals Limited keeps ₹8 of every ₹100 of revenue as net profit.
Cash quality
2.5×Cash from Glenmark Pharmaceuticals Limited's business was 2.5× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
19.3×Glenmark Pharmaceuticals Limited's operating profit covered its interest costs 19.3 times in the year to Mar 2026.
Cash vs debt
Net cashGlenmark Pharmaceuticals Limited held ₹607 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Glenmark Pharmaceuticals Limited's P/E ratio?
Investors pay ₹34.5 for every ₹1 of Glenmark Pharmaceuticals Limited's yearly profit, lower than 55% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Glenmark Pharmaceuticals Limited: ₹62,047 Cr ÷ ₹10,512 Cr (31 Mar 2026) = 5.9.
What is Glenmark Pharmaceuticals Limited's return on equity?
Glenmark Pharmaceuticals Limited earned 17.1% on its shareholders' money over the last year, higher than 67% of Healthcare companies in India.
How much does Glenmark Pharmaceuticals Limited owe compared with what it owns?
Glenmark Pharmaceuticals Limited owes ₹0.47 for every ₹1 it owns (low), higher than 78% of Healthcare companies in India.
Does Glenmark Pharmaceuticals Limited pay a dividend?
Yes. Glenmark Pharmaceuticals Limited pays 0.11% of its share price as dividends a year, lower than 86% of dividend-paying Healthcare companies in India.
Is Glenmark Pharmaceuticals Limited's revenue growing?
Revenue rose 27% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.